• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 7, 2014

View Archived Issues

Rockwell garners ODAC support with first drug out of the gate

The Oncologic Drugs Advisory Committee (ODAC) gave a green light Thursday to Rockwell Medical Inc.'s lead candidate, an iron maintenance therapy for dialysis patients with stage V chronic kidney disease. Read More

Macrelin CRL darkens Aeterna sunshine; phase III found far from spotles

Investors this morning will find out more about the fate of Aeterna Zentaris Inc.'s new drug application (NDA) for Macrilen (macimorelin), an oral ghrelin agonist for use as a diagnostic in evaluating adult growth hormone deficiency (AGHD) in the wake of a complete response letter (CRL) from U.S. regulators. Read More

Avalanche of ASH abstracts draws swift reaction on Wall Street

Investors and analysts scrambled Thursday to divine portent from a heap of newly released abstracts previewing December's American Society of Hematology (ASH) annual meeting. Karyopharm Therapeutics Inc. led the pack of abstract news gainers, with shares (NASDAQ:KPTI) rising 10.7 percent to $41.73 on news that its lead candidate, selinexor (KPT-330), demonstrated a disease control rate of 80 percent in 10 patients with relapsed and refractory aggressive non-Hodgkin's lymphoma (NHL). Read More

Aegerion picks up Amylin-developed drug in $325M cash deal

Less than a week after reporting disappointing third quarter earnings, Aegerion Pharmaceuticals Inc. cheered the Street by disclosing an agreement with Astrazeneca plc to acquire the approved orphan drug Myalept (metreleptin for injection) for $325 million up front, with no milestones or royalties attached. Read More

Cautious optimism on device tax repeal, but doubts to tax reform

WASHINGTON – Device makers are keeping a close eye on developments in the nation's capital after the Nov. 4 GOP landslide, and opponents of the device tax and supporters of tax reform excited about the prospects that Congress will move bills to address both issues. Read More

Earnings

Discovery Laboratories Inc., of Warrington, Pa., said third quarter sales of Surfaxin (lucinactant) to the company's specialty distributor totaled about $219,000 and said demand sales into hospitals grew about 60 percent to $116,000 compared to the second quarter of 2014. Read More

Stock movers

Read More

Financings

Mast Therapeutics Inc., of San Diego, said it priced a public offering expected to raise gross proceeds of about $21 million. Read More

Other news to note

Cardio3 Biosciences SA, of Mont-Saint-Guibert, Belgium, acquired medical device firm Corquest Medical Inc., of Miami, which specializes in the development of devices and technologies for cardiac surgery. Read More

In the clinic

Genmab A/S, of Copenhagen, Denmark, offered additional data from the interim analysis of the Arzerra (ofatumumab) phase III study, PROLONG (OMB112517). The study evaluated ofatumumab maintenance therapy vs. no further treatment (observation) in patients with a complete response or partial response after second- or third-line treatment for chronic lymphocytic leukemia. Read More

Pharma: Other news to note

Ipsen SA, of Paris, said the FDA approved a new device to deliver Somatuline Depot (lanreotide). The single-use syringe is available in 60 mg, 90 mg and 120 mg dosages and includes additional safety features. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe